MK-2870 in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer With Programmed Cell Death Ligand 1 Tumor Proportion Score ≥ 50%
The primary objective of the study is to compare MK-2870 combined with pembrolizumab to pembrolizumab alone with respect to overall survival (OS). The primary hypothesis is that the combination of MK-2870